UnitedHealth’s strong Q2 2026 results, featuring an adjusted EPS beat of $6.38 versus consensus near $5.22 and a subsequent raise in full-year 2026 adjusted EPS guidance to $19.50–$20.00, underpin the 82% market-implied probability of another beat on the October 13 report. Medicare Advantage margins have expanded above 3% with better-than-expected medical cost trends and enrollment attrition, while Optum segments show continued operating leverage. Analyst estimates for Q3 EPS cluster around $4.00–$4.15, and the company’s recent track record of outperformance plus positive September management commentary on durable cost controls support trader consensus reflected in current Polymarket odds.